Phase 2 Focal Segmental Glomerulosclerosis Clinical Trials
7 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–7 of 7 trials
Recruiting
Phase 2
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI)30 enrolled1 locationNCT06664814
Recruiting
Phase 2
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis
Akebia Therapeutics60 enrolled10 locationsNCT07268638
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi84 enrolled69 locationsNCT06500702
Recruiting
Phase 2
Study of WAL0921 in Patients With Glomerular Kidney Diseases
Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences96 enrolled50 locationsNCT06466135
Recruiting
Phase 1Phase 2
AMPK-activation by Metformin in FSGS: AMP-FSGS
Focal Segmental Glomerulosclerosis
Yale University30 enrolled2 locationsNCT06090227
Recruiting
Phase 2
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Alport SyndromeFocal Segmental GlomerulosclerosisImmunoglobulin A Nephropathy+2 more
Travere Therapeutics, Inc.67 enrolled47 locationsNCT05003986
Completed
Phase 2
Study to assess the safety and effectiveness of propagermanium as add-on therapy in FSGS patients who are already taking Irbesartan.
Focal Segmental Glomerulosclerosis
Dimerix Ltd10 enrolled12 locationsACTRN12618000910202